• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Controlled ocular delivery of acyclovir through rate controlling ocular insert of Eudragit: a technical note.通过Eudragit控释眼用插入剂实现阿昔洛韦的眼部控释给药：技术说明
AAPS PharmSciTech. 2008;9(1):169-73. doi: 10.1208/s12249-008-9032-1. Epub 2008 Jan 25.
2
Eudragit microparticles as a possible tool for ophthalmic administration of acyclovir.作为阿昔洛韦眼部给药可能工具的Eudragit微粒
J Microencapsul. 2007 Aug;24(5):445-56. doi: 10.1080/02652040701374889.
3
Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye?
Biomed Mater Eng. 2004;14(4):383-93.
4
Floating properties and release characteristics of hollow microspheres of acyclovir.阿昔洛韦中空微球的漂浮性能及释放特性
Drug Deliv. 2008 Jun;15(5):331-41. doi: 10.1080/10717540802035335.
5
Bioadhesive microspheres for ophthalmic administration of acyclovir.用于阿昔洛韦眼部给药的生物粘附微球。
J Pharm Pharmacol. 1997 Aug;49(8):737-42. doi: 10.1111/j.2042-7158.1997.tb06103.x.
6
Controlled release polymeric ocular delivery of acyclovir.阿昔洛韦的控释聚合物眼用给药系统。
Pharm Dev Technol. 2010 Jul-Aug;15(4):369-78. doi: 10.3109/10837450903262017.
7
In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery.用于持续给药的载阿昔洛韦的尤特奇RLPO（®）纳米颗粒的体外释放
Int J Biol Macromol. 2014 Jun;67:478-82. doi: 10.1016/j.ijbiomac.2014.04.019. Epub 2014 Apr 19.
8
Future of contact lens usage.隐形眼镜使用的未来。
Cont Lens Anterior Eye. 2013 Aug;36(4):155. doi: 10.1016/j.clae.2013.05.001.
9
Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review.用于新型隐形眼镜基眼用药物递送系统的聚合物水凝胶：综述
Cont Lens Anterior Eye. 2008 Apr;31(2):57-64. doi: 10.1016/j.clae.2007.09.002. Epub 2007 Oct 25.
10
Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments.影响眼膏剂产品质量和体外性能的处方和工艺因素
Int J Pharm. 2015 Sep 30;493(1-2):412-25. doi: 10.1016/j.ijpharm.2015.07.066. Epub 2015 Jul 29.

引用本文的文献

1
Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers.抗病毒传递系统的进展及壳聚糖基聚合物和纳米颗粒抗病毒药物和抗病毒载体。
Viruses. 2023 Feb 28;15(3):647. doi: 10.3390/v15030647.
2
Ophthalmic drug dosage forms: characterisation and research methods.眼科药物剂型：特性与研究方法
ScientificWorldJournal. 2014 Mar 18;2014:861904. doi: 10.1155/2014/861904. eCollection 2014.
3
Ocular insert for sustained delivery of gatifloxacin sesquihydrate: Preparation and evaluations.用于持续递送加替沙星倍半水合物的眼用插入剂：制备与评价。
Int J Pharm Investig. 2012 Apr;2(2):70-7. doi: 10.4103/2230-973X.100040.

本文引用的文献

1
Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability.制备条件对载阿昔洛韦聚（d，l-乳酸）纳米球的影响及聚乙二醇包衣对眼部药物生物利用度的作用
Pharm Res. 2003 Apr;20(4):584-90. doi: 10.1023/a:1023290514575.
2
A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide).基于聚环氧乙烷的可蚀性眼用插入剂中不同眼科药物释放机制的研究。
Eur J Pharm Biopharm. 2002 Sep;54(2):193-9. doi: 10.1016/s0939-6411(02)00086-3.
3
Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs.利用含眼用插入物的亲脂性前药实现替利洛尔的控释和眼部吸收。
J Control Release. 2001 Oct 19;76(3):255-63. doi: 10.1016/s0168-3659(01)00441-2.
4
Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.聚乙二醇（PEG）包被的聚乙基-2-氰基丙烯酸酯纳米球包裹的阿昔洛韦的眼内耐受性和体内生物利用度
J Pharm Sci. 2001 Mar;90(3):288-97. doi: 10.1002/1520-6017(200103)90:3<288::aid-jps4>3.0.co;2-5.
5
Ocular delivery systems of pefloxacin mesylate.
Pharmazie. 1999 Jan;54(1):55-8.
6
Bioadhesive microspheres for ophthalmic administration of acyclovir.用于阿昔洛韦眼部给药的生物粘附微球。
J Pharm Pharmacol. 1997 Aug;49(8):737-42. doi: 10.1111/j.2042-7158.1997.tb06103.x.
7
Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy.更昔洛韦眼用凝胶治疗兔单纯疱疹病毒性角膜炎：眼内渗透及疗效
J Ocul Pharmacol. 1994 Summer;10(2):439-51. doi: 10.1089/jop.1994.10.439.
8
Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.阿昔洛韦。对其抗病毒活性、药代动力学特性及治疗效果的重新评估。
Drugs. 1994 Jan;47(1):153-205. doi: 10.2165/00003495-199447010-00009.
9
Ocular drug delivery. Pharmacokinetic considerations.眼部药物递送。药代动力学考量。
Clin Pharmacokinet. 1990 Apr;18(4):255-69. doi: 10.2165/00003088-199018040-00001.

Controlled ocular delivery of acyclovir through rate controlling ocular insert of Eudragit: a technical note.

作者信息

Khan Shagufta, Ali Asgar, Singhavi Dilesh, Yeole Pramod

机构信息

Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, 442001 Maharashtra, India.

出版信息

AAPS PharmSciTech. 2008;9(1):169-73. doi: 10.1208/s12249-008-9032-1. Epub 2008 Jan 25.

DOI:10.1208/s12249-008-9032-1
PMID:18446478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2976891/
Abstract
摘要